Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, Møller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer. 2012;75(3):280–4.

Article  PubMed  Google Scholar 

Wang S, Tang J, Sun T, Zheng X, Li J, Sun H, Zhou X, Zhou C, Zhang H, Cheng Z, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep. 2017;7(1):1339.

Article  PubMed  PubMed Central  Google Scholar 

Small Lung Cell Cancer. (Version 3.2023) [https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf].

Petty WJ, Paz-Ares L. Emerging strategies for the treatment of small cell lung Cancer: a review. JAMA Oncol. 2023;9(3):419–29.

Article  PubMed  Google Scholar 

Lee SM, Woll PJ, Rudd R, Ferry D, O’Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009;101(15):1049–57.

Article  CAS  PubMed  Google Scholar 

Lu S, Li L, Luo Y, Zhang L, Wu G, Chen Z, Huang C, Guo S, Zhang Y, Song X, et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2015;10(1):206–11.

Article  CAS  Google Scholar 

Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, et al. Nivolumab and Ipilimumab as maintenance therapy in extensive-disease small-cell Lung Cancer: CheckMate 451. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39(12):1349–59.

Article  CAS  Google Scholar 

Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, et al. Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: a multicenter, randomized, phase 3 trial. Lung Cancer (Amsterdam Netherlands). 2019;134:121–6.

Article  PubMed  Google Scholar 

Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung Cancer: a Randomized, Double-Blind, placebo-controlled phase II Study-CALGB 30504 (Alliance). J Clin Oncology: Official J Am Soc Clin Oncol. 2015;33(15):1660–5.

Article  CAS  Google Scholar 

Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N. PARP inhibitors in ovarian Cancer: the Route to Ithaca. Diagnostics (Basel) 2019, 9(2).

Murai J, Pommier Y. PARP trapping beyond homologous recombination and platinum sensitivity in cancers. Annual Rev Cancer Biology. 2019;3(1):131–50.

Article  Google Scholar 

Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2(9):798–811.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564–9.

Article  CAS  PubMed  Google Scholar 

Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110–20.

Article  CAS  PubMed  Google Scholar 

Sivanand S, Rhoades S, Jiang Q, Lee JV, Benci J, Zhang J, Yuan S, Viney I, Zhao S, Carrer A, et al. Nuclear Acetyl-CoA production by ACLY promotes homologous recombination. Mol Cell. 2017;67(2):252–e265256.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aird KM, Worth AJ, Snyder NW, Lee JV, Sivanand S, Liu Q, Blair IA, Wellen KE, Zhang R. ATM couples replication stress and metabolic reprogramming during cellular senescence. Cell Rep. 2015;11(6):893–901.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bian X, Lin W. Targeting DNA replication stress and DNA double-strand break repair for optimizing SCLC Treatment. Cancers (Basel) 2019, 11(9).

Ragu S, Droin N, Matos-Rodrigues G, Barascu A, Caillat S, Zarkovic G, Siberchicot C, Dardillac E, Gelot C, Guirouilh-Barbat J, et al. A noncanonical response to replication stress protects genome stability through ROS production, in an adaptive manner. Cell Death Differ. 2023;30(5):1349–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vanzo R, Bartkova J, Merchut-Maya JM, Hall A, Bouchal J, Dyrskjøt L, Frankel LB, Gorgoulis V, Maya-Mendoza A, Jäättelä M, et al. Autophagy role(s) in response to oncogenes and DNA replication stress. Cell Death Differ. 2020;27(3):1134–53.

Article  CAS  PubMed  Google Scholar 

Fournier LA, Kumar A, Stirling PC. Chromatin as a platform for modulating the replication stress response. Genes (Basel) 2018, 9(12).

Hirai T, Shirai H, Fujimori H, Okayasu R, Sasai K, Masutani M. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation. Cancer Sci. 2012;103(6):1045–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Césaire M, Thariat J, Candéias SM, Stefan D, Saintigny Y, Chevalier F. Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer? Int J Mol Sci 2018, 19(12).

Wang H, Ren B, Liu Y, Jiang B, Guo Y, Wei M, Luo L, Kuang X, Qiu M, Lv L, et al. Discovery of Pamiparib (BGB-290), a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor in Clinical Development. J Med Chem. 2020;63(24):15541–63.

Article  CAS  PubMed  Google Scholar 

Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, Wang X, Gao Y, Yu F, Su D, et al. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia. 2020;22(9):431–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Markham A. Pamiparib: first approval. Drugs. 2021;81(11):1343–8.

Article  CAS  PubMed  Google Scholar 

Xu B, Sun T, Shi Y, Cui J, Yin Y, Ouyang Q, Liu Q, Zhang Q, Chen Y, Wang S, et al. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. Breast Cancer Res Treat. 2023;197(3):489–501.

Article  CAS  PubMed  Google Scholar 

Wu X, Zhu J, Wang J, Lin Z, Yin R, Sun W, Zhou Q, Zhang S, Wang D, Shi H, et al. Pamiparib Monotherapy for patients with germline BRCA1/2-Mutated ovarian Cancer previously treated with at Least Two Lines of Chemotherapy: a Multicenter, Open-Label, phase II study. Clin Cancer Research: Official J Am Association Cancer Res. 2022;28(4):653–61.

Article  CAS  Google Scholar 

Lickliter JD, Voskoboynik M, Mileshkin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M. Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. Br J Cancer. 2022;126(4):576–85.

Article  CAS  PubMed  Google Scholar 

Friedlander M, Meniawy T, Markman B, Mileshkin L, Harnett P, Millward M, Lundy J, Freimund A, Norris C, Mu S, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019;20(9):1306–15.

Article  CAS  PubMed  Google Scholar 

Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4–12 STIMULI trial. Annals Oncology: Official J Eur Soc Med Oncol. 2022;33(1):67–79.

Article  CAS  Google Scholar 

Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(3):321–31.

Article  PubMed  Google Scholar 

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–25.

Article  PubMed  PubMed Central  Google Scholar 

de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, et al. Phase I, Dose-Escalation, two-part trial of the PARP inhibitor Talazoparib in patients with Advanced Germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620–9.

Article  PubMed  PubMed Central  Google Scholar 

Ai X, Pan Y, Shi J, Yang N, Liu C, Zhou J, Zhang X, Dong X, He J, Li X, et al. Efficacy and safety of Niraparib as maintenance treatment in patients with extensive-stage SCLC after First-Line chemotherapy: a Randomized, Double-Blind, phase 3 study. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16(8):1403–14.

Article  CAS  Google Scholar 

Thomas A, Vilimas R, Trindade C, Erwin-Cohen R, Roper N, Xi L, Krishnasamy V, Levy E, Mammen A, Nichols S, et al. Durvalumab in Combination with Olaparib in patients with relapsed SCLC: results from a phase II study. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2019;14(8):1447–57.

Article  CAS  Google Scholar 

Woll P, Gaunt P, Danson S, Steele N, Ahmed S, Mulatero C, Shah R, Bhosle J, Hodgkinson E, Watkins B, et al. Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): a randomised, double-blind, placebo-controlled phase II trial. Lung Cancer (Amsterdam Netherlands). 2022;171:26–33.

Article  CAS  PubMed